Comparison Chart Astellas Pharma Inc. OTC Markets

ALPMY

US04623U1025

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	ASTELLAS PHARMA INC.	Other Pharmaceuticals	-0.28%	-1.66%	+6.85%	+31.36%	-18.11%	25.47B	-	-	-

10-08	Vir Biotechnology's VIR-5500 Gets FDA Fast Track Designation for Prostate Cancer	MT
10-08	Vir Biotechnology, Inc. and Astellas Pharma Inc. Announce FDAFast Track Designation for PSMA-Targeted Pro-XTEN® Dual-Masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer	CI

Market Closed - OTC Markets 15:59:59 2026-10-08 EDT			5-day change	1st Jan Change
14.20 ^USD	-0.28%		-1.66%	+6.85%

Comparison Chart Astellas Pharma Inc. OTC Markets

Stocks

ALPMY

US04623U1025

Pharmaceuticals

Compared values